SecBot SecBot
8-K ·Filed Nov 10, 2026

TLSI

TriSalus Life Sciences, Inc.
BEARISH
Impact 6/10
Horizonmonths Processed7d 8h ago SEC0001628280-26-072513
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The guidance cut to $46M-$48M implies a sharp deceleration in H2 2026 vs the prior outlook, suggesting the commercial expansion is not yet translating to expected revenue. Monitor Q4 results for whether the TriNav Advance launch and CMS reimbursement changes can re-accelerate growth in 2027.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$2.85
T+0 close · Nov 10, 2026 · via day close
Latest settled
−19.30%
T+1 · $2.30
Vs SPY
−20.62%
α at T+1
Next horizon
T+5
due 9h ago
  1. T+0 · Nov 10 $2.85entry
  2. T+1 · 6d ago −19.30%α −20.62% · $2.30
  3. T+5 · due 9h ago Pending
  4. T+5 · todayOpen
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

TriSalus Life Sciences reported Q3 2026 revenue of $12.9M (+11.3% YoY), above the $14.0M consensus, but revised full-year 2026 revenue guidance down to $46M-$48M (2-6% growth vs 2025), well below the prior $54M-$57M range. CMS finalized favorable 2027 reimbursement rate increases for PEDD procedures, but the guidance cut signals slower-than-expected commercial ramp.

Key Financial Metrics

EPS
−$0.15
est −$0.13 · -15.4%
Revenue
$12.9M
est $14.0M · -8.0% · +11.3% YoY
Rating
strong miss
Guidance
$46M-$48M
lowered
Gross Margin
86.2%

Key Facts

  • Q3 2026 revenue $12.9M, +11.3% YoY from $11.6M
  • Full-year 2026 revenue guidance revised to $46M-$48M from prior $54M-$57M
  • GAAP diluted EPS -$0.15 vs -$0.96 YoY; consensus was -$0.13
  • Gross margin 86.2% vs 83.5% YoY
  • Operating loss -$7.7M improved from -$9.0M YoY
  • Cash $41.1M at Sep 30, 2026; raised $46M in Q1 equity offering
  • CMS finalized 2027 PEDD reimbursement increase from ~$11,794 to ~$20,910 per procedure
  • FDA clearance received for TriNav Advance enabling PEDD in small distal vessels

Financial Impact

Revenue guidance cut by ~$8M-$9M from prior midpoint; Q3 revenue $12.9M missed $14.0M consensus by 7.9%

revenueguidanceeps

Risk Factors

  • Revised guidance implies H2 revenue well below prior expectations; commercial team productivity ramping slower than anticipated
  • Cash burn continues; $41.1M at Sep 30 may require additional financing before reaching profitability
  • Dependence on CMS reimbursement changes and FDA clearance for growth inflection

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-072513
Document: tlsi-20261110.htm0001628280-26-072513
Document: 0001628280-26-072513-index-headers.html0001628280-26-072513
Document: 0001628280-26-072513-index.html0001628280-26-072513
Document: 0001628280-26-072513.txt0001628280-26-072513
8-K Data (Synthetic)0001628280-26-072513

Track record

7 reports on TLSI

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 17, 2026today Insider Cluster Neutral 3/10 Entry $2.20 Now $2.30 +4.32% settles Nov 19
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $2.27 Now $2.30 +1.10% settles Nov 18
  3. Nov 10, 20267d ago 8-K Bearish 6/10 Viewing Entry $2.85 to $2.30 Now $2.30 +19.47% ▲ +19.30% +20.62% vs SPY
  4. Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $3.64 to $3.77 Now $2.30 −36.95% ▲ +3.57% +3.03% vs SPY
  5. Jun 11, 202622w ago Institutional Cluster Bullish 4/10 Entry $3.64 to $3.77 Now $2.30 −36.95% ▲ +3.57% +3.03% vs SPY
  6. Mar 11, 202635w ago Insider Cluster Neutral 3/10 Entry $4.16 to $4.10 Now $2.30 −44.83% ▼ −1.44% +0.04% vs SPY
  7. Mar 5, 202636w ago 8-K Bullish 8/10 Entry $4.47 to $4.62 Now $2.30 −48.60% ▲ +3.36% +2.51% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens Wed (17h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026